Edgewise Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm the senior biotech analyst at JPMorgan, or one of them. Our next presenting company is Edgewise Therapeutics and presenting on behalf of the company, we have CEO, Kevin Koch. Kevin?
Okay. Well, thank you all for coming and thanks for the invitation. It's been a great year of '23 and even better '24 for Edgewise therapeutics. Here's my forward-looking statements.
Yes. Okay. So Edgewise Therapeutics is a research and development biotech company targeting muscle for the treatment of rare unmet medical need diseases. We've had rapidly advance our drug for muscular dystrophy now in pivotal studies, EDG-5506 in Becker muscular dystrophy and additional data coming this year.
In addition, muscular dystrophy, we've also moved into clinical development, EDG-7500, which is a novel mechanism for the treatment of hypertrophic cardiomyopathy. And again, we are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
